Loading
Acurx Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by LUCI DAVID P, was filed 08 Jan 2025.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€514,244
13 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleCarl Sailer1 buy
David P. Luci1 buy
Jack H. Dean1 buy
James J. Donohue1 buy
Joseph C. Scodari1 buy
Robert J. Deluccia1 buy
Since the insiders bought
- -81.9%Entry US$16.16 · Close at T+365 US$2.93
- -81.9%Entry US$16.16 · Close at T+365 US$2.93
- -81.9%Entry US$16.16 · Close at T+365 US$2.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.14
Analyst consensus
3 analysts1.33/5
US$10.00Target US$17.00(+1391%)US$31.00
Income statement
EBITDA-US$8.1M
Net income-US$8M0.0% margin
Valuation
PER (forward)-0.7x
P/Book0.7x
Beta-2.05
Balance sheet & cash
Market capUS$6.3M
Free Cash Flow-US$6.8M
Profitability & ownership
ROE-128.1%
ROA-55.9%
% insiders2.3%
% institutions3.6%
Last declaration on 8 January 2025
Declarations19 total
9,852 shares@ US$1.015100.0% of flowCommon StockSEC:0001104659-25-002046:0
Canonical exit: 6 Apr 2025 (T+90)
24,631 shares@ US$1.0159.8% of flowCommon StockSEC:0001104659-25-002053:0
Canonical exit: 6 Apr 2025 (T+90)
24,631 shares@ US$1.015100.0% of flowCommon StockSEC:0001104659-25-002054:0
Canonical exit: 6 Apr 2025 (T+90)
9,852 shares@ US$1.015100.0% of flowCommon StockSEC:0001104659-25-002051:0
Canonical exit: 6 Apr 2025 (T+90)
49,261 shares@ US$1.01523.3% of flowCommon StockSEC:0001104659-25-002052:0
Canonical exit: 6 Apr 2025 (T+90)
49,261 shares@ US$1.01533.8% of flowCommon StockSEC:0001104659-25-002050:0
Canonical exit: 6 Apr 2025 (T+90)
19,737 shares@ US$3.5526.0% of flowCommon StockSEC:0001104659-24-005357:0
40,000 shares0Common StockSEC:0001104659-24-001375:1
30,000 shares0Common StockSEC:0001104659-24-001375:2
19,737 shares@ US$3.5530.8% of flowCommon StockSEC:0001104659-24-001375:3
19,737 shares@ US$3.5530.8% of flowCommon StockSEC:0001104659-24-001373:0
40,000 shares0Common StockSEC:0001104659-24-001375:0
19,737 shares@ US$3.8035.3% of flowCommon StockSEC:0001104659-22-084315:0
Canonical exit: 25 Oct 2022 (T+90)
19,737 shares@ US$3.8029.7% of flowCommon StockSEC:0001104659-22-084317:0
Canonical exit: 25 Oct 2022 (T+90)
19,737 shares@ US$3.8051.1% of flowCommon StockSEC:0001104659-22-084316:0
Canonical exit: 25 Oct 2022 (T+90)
5,161 shares@ US$4.849.0% of flowCommon StockSEC:0001104659-21-143551:0
Canonical exit: 21 Feb 2022 (T+90)
5,034 shares@ US$4.90115.1% of flowCommon StockSEC:0001104659-21-142473:0
Canonical exit: 17 Feb 2022 (T+90)
5,200 shares@ US$4.8010.6% of flowCommon StockSEC:0001104659-21-142471:0
Canonical exit: 17 Feb 2022 (T+90)
12,500 shares@ US$6.0025.5% of flowCommon StockSEC:0001104659-21-114674:0
Canonical exit: 27 Sept 2021 (T+90)
19 of 19 declarations
About Acurx Pharmaceuticals, Inc.
On January 6, 2025, 6 filers at Acurx Pharmaceuticals, Inc. bought on the same day for EUR 164,963 in total, which is 12 of the 13 purchases on file. The record has 19 filings published between September 10, 2021 and January 8, 2025, with no sale: 13 purchases worth EUR 514,244 (median EUR 24,260), 3 option exercises and 3 filings of another kind.
On July 27, 2022, David P. Luci (President and CEO), Carl Sailer and Robert J. Deluccia (both directors) each bought EUR 73,463, the three largest amounts in the record. Robert J. Deluccia is the most frequent with 7 filings of which 3 purchases, ahead of Carl Sailer (5, of which 4 purchases) and David P. Luci (4, of which 3 purchases). Jack H. Dean and Joseph C. Scodari, directors, have one purchase each.
Read moreShow less
Activity is split into 4 filings in 2021, 3 in 2022, 6 in 2024 and 6 in 2025. The US health care company, listed on Nasdaq, is worth USD 6.3 million and insiders hold 2.3% of it. The 13 purchases carrying a 90-day return come out at a stored median of -26%, none positive: past results on record, not a forecast.
